Active — Not RecruitingNot Applicable

Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)

Canada57 participantsStarted 2021-08-05

Plain-language summary

The study will focus on cardiac blood and imaging biomarkers to facilitate early recognition of patients at risk for myocardial injury after COVID-19 vaccination. Ultimately, the intention is to identify patients at risk, reduce adverse events, and determine the need for longer-term follow-up in patients with myocardial injury after vaccination.

Who can participate

Age range17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 17 years (both Cohort A and B)
✓. Received at least one dose of a COVID-19 vaccine in the past 6 months (both Cohort A and B)
✓. Developed new clinical signs or symptoms suggestive of myocarditis/myocardial injury within one month of COVID vaccine administration without other known cause (Cohort A, only)

Exclusion criteria

✕. Contraindications to cardiac PET/MRI
✕. Current history of COVID-19

What they're measuring

Prevalence of myocardial inflammation on PET/MRI

Timeframe: 6months and 12months

Trial details

NCT IDNCT04967807

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08-05

View on ClinicalTrials.gov More Myocardial Injury trials